These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Beta-blocker therapy in heart failure in the elderly. Fu M Int J Cardiol; 2008 Apr; 125(2):149-53. PubMed ID: 18023898 [TBL] [Abstract][Full Text] [Related]
28. Management of congestive heart failure: is the role of positive inotropic therapy fading? Futterman LG; Lemberg L Am J Crit Care; 1996 Nov; 5(6):455-60. PubMed ID: 8922162 [TBL] [Abstract][Full Text] [Related]
29. Levosimendan: current status and future prospects. Archan S; Toller W Curr Opin Anaesthesiol; 2008 Feb; 21(1):78-84. PubMed ID: 18195615 [TBL] [Abstract][Full Text] [Related]
31. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker). Dimopoulos K; Salukhe TV; Coats AJ; Mayet J; Piepoli M; Francis DP Int J Cardiol; 2004 Feb; 93(2-3):105-11. PubMed ID: 14975535 [TBL] [Abstract][Full Text] [Related]
32. Tolerability to beta-blocker therapy among heart failure patients in clinical practice. Butler J; Khadim G; Belue R; Chomsky D; Dittus RS; Griffin M; Wilson JR J Card Fail; 2003 Jun; 9(3):203-9. PubMed ID: 12815570 [TBL] [Abstract][Full Text] [Related]
33. Why do patients fail to receive beta-blockers for chronic heart failure over time? A "real-world" single-center, 2-year follow-up experience of beta-blocker therapy in patients with chronic heart failure. Parameswaran AC; Tang WH; Francis GS; Gupta R; Young JB Am Heart J; 2005 May; 149(5):921-6. PubMed ID: 15894978 [TBL] [Abstract][Full Text] [Related]
34. Digoxin in patients with heart failure. Böhm M N Engl J Med; 1997 Jul; 337(2):129-30; author reply 130-1. PubMed ID: 9221339 [No Abstract] [Full Text] [Related]
35. Evolving concepts in the treatment of heart failure: should new inotropic agents carry promise or paranoia? Young JB Pharmacotherapy; 1996; 16(2 Pt 2):78S-84S. PubMed ID: 8668609 [TBL] [Abstract][Full Text] [Related]
36. Rationale and design of the enoximone clinical trials program. Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960 [TBL] [Abstract][Full Text] [Related]
37. Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade. Pitt B; Fonarow GC; Gheorghiade M; Deedwania PC; Duprez DA Am J Cardiol; 2006 May; 97(10A):26F-33F. PubMed ID: 16698332 [TBL] [Abstract][Full Text] [Related]
38. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075 [TBL] [Abstract][Full Text] [Related]
39. The clinical experience with levosimendan in anesthesiology and in the intensive care unit. Cavana M; Pignataro C; Fraticelli A; Mebazaa A Ital Heart J; 2003 May; 4 Suppl 2():61S-64S. PubMed ID: 14635372 [TBL] [Abstract][Full Text] [Related]
40. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure. Sabbah HN; Imai M; Cowart D; Amato A; Carminati P; Gheorghiade M Am J Cardiol; 2007 Jan; 99(2A):41A-46A. PubMed ID: 17239704 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]